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Replication of functional serotonin receptor type 3A
and B variants in bipolar affective disorder: a European
multicenter study
C Hammer1, S Cichon2,3,4, TW Mu¨hleisen2,4, B Haenisch2,4, F Degenhardt2,4, M Mattheisen2,4,5,6, R Breuer7, SH Witt7, J Strohmaier7,
L Oruc8, F Rivas9, G Babadjanova10, M Grigoroiu-Serbanescu11, J Hauser12, R Ro¨th1,13, G Rappold1, M Rietschel7, MM No¨then2,4,14
and B Niesler1,13
Serotonin type 3 receptors (5-HT3) are involved in learning, cognition and emotion, and have been implicated in various
psychiatric phenotypes. However, their contribution to the pathomechanism of these disorders remains elusive. Three single
nucleotide polymorphisms (SNPs) in the HTR3A and HTR3B genes (rs1062613, rs1176744 and rs3831455) have been associated
with bipolar affective disorder (BPAD) in pilot studies, and all of them are of functional relevance. We performed a European
multicenter study to confirm previous results and provide further evidence for the relevance of these SNPs to the etiology of
neuropsychiatric disorders. This involved analysis of the distribution of the three SNPs among 1804 BPAD cases and 2407 healthy
controls. A meta-analysis revealed a pooled odds ratio of 0.881 (P¼ 0.009, 95% confidence intervals¼ 0.802–0.968) for the non-
synonymous functional SNP HTR3B p.Y129S (rs1176744), thereby confirming previous findings. In line with this, the three genome-
wide association study samples BOMA (Bonn-Mannheim)-BPAD, WTCCC (Wellcome Trust Case Control Consortium)-BPAD and
GAIN (Genetic Association Information Network)-BPAD, including 43500 patients and 5200 controls in total, showed an
overrepresentation of the p.Y129 in patients. Remarkably, the meta-analysis revealed a P-value of 0.048 (OR¼ 0.934, fixed effect
model). We also performed expression analyses to gain further insights into the distribution of HTR3A and HTR3B mRNA in the
human brain. HTR3A and HTR3B were detected in all investigated brain tissues with the exception of the cerebellum, and large
differences in the A:B subunit ratio were observed. Interestingly, expression of the B subunit was most prominent in the brain stem,
amygdalae and frontal cortex, regions of relevance to psychiatric disorders. In conclusion, the present study provides further
evidence for the presence of impaired 5-HT3 receptor function in BPAD.
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Introduction
Serotonin type 3 (5-HT3) receptors are involved in neural
processes related to cognition and emotion, and antagonists of
these receptors have been shown to be beneficial in the
treatment of various psychiatric disorders. In particular,
improvement in depressive symptoms, memory and cognition
have been described in psychiatric patients.1 Furthermore,
distinct 5-HT3 receptor variants have been implicated in the
pathophysiology of bipolar affective disorder (BPAD), schizo-
phrenia and eating disorders.2 Functional receptors contain
five subunits of diverse composition. In humans, 5-HT3
subunits are encoded by five genes: HTR3A–E. Of these
subunits, the 5-HT3A and 5-HT3B have been characterized
most extensively. In vitro studies have shown that only the
5-HT3A subunit is capable of forming functional homopentameric
receptors whereas the other subunits require 5-HT3A to build
heteropentameric complexes.3 Comparative expression ana-
lyses of all five HTR3 genes on the mRNA level, using
conventional PCR have shown that expression of the 5-HT3E
subunit is restricted to certain tissues of the gastrointestinal
tract, whereas the other subunits are expressed ubiquitously.4
Early studies in the 1990s using radioligand binding revealed
5-HT3 selective binding in distinct brain regions. Different
ligand-binding densities were observed in the forebrain
regions analyzed, depending on the radioligand used; for
example, zacopride, LY278584 or granisetron.5–8 However,
5-HT3Awas the only known subunit of this type of receptors at
that time, the complexity of the human 5-HT3 receptor system
first became apparent during the last decade, and the
composition of native receptor subtypes remains elusive.2
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Consequently, the difference in binding density depending on
the applied ligand may reflect the existence of receptor
subtypes of differing compositions and affinities.3 Although
expression ofHTR3A has been reported in the cerebral cortex,
amygdala, hippocampus, caudate and thalamus on themRNA
level in humans9,10 contradictory data exist concerning the
expression of HTR3B in the central nervous system.11
In two pilot case–control studies, the variants HTR3A
c.42C4T (rs1062613) and HTR3B p.Y129S (c.386A4C,
rs1176744), as well as the small deletion HTR3B
c.104_102delAGA (rs3831455) were found to be asso-
ciated with BPAD.12,13
All of these variants have been shown to exhibit functional
effects in vitro.13–19 Furthermore, the two single nucleotide
exchanges have also been implicated in anorexia nervosa
and irritable bowel syndrome, both of which show high
comorbidity with anxiety and depression,14,20 whereas
HTR3B p.Y129S appears to have a role in major depres-
sion.21 In addition, HTR3A c.42C4T has been correlated
with altered amygdala activity and increased anxiety scores in
paradigms testing emotional response in vivo.22,23
The identification of identical risk variants for different
psychiatric phenotypes supports the hypothesis that in spite of
discriminable clinical diagnoses, these phenotypes share
some aspects of the underlying biology.24 The aim of the
present European multicenter study was to confirm the
previous association findings and provide further evidence
for the hypothesis that functional HTR3 variants are impli-
cated in the etiology of various psychiatric disorders. We
successfully replicated the association between the HTR3B
variant p.Y129S (rs1176744) and BPAD in a large European
case–control cohort consisting of 41800 cases and 2400
controls. Furthermore, we were able to confirm co-expression
of both the 5-HT3A and 5-HT3B subunits in brain structures of
relevance to anxiety and depression.
Materials and methods
European patient–control samples. All protocols and
procedures were approved by the respective local Ethics
Committees. Written informed consent was obtained from all
study participants before the study participation. All patients
were assigned a lifetime diagnosis of BPAD type I or type II.
This was based on Diagnostic and Statistical Manual of
Mental Disorders-IV criteria and a consensus best-estimate
procedure, including a structured interview-I, review of
medical records, the family history method and the
Operational Criteria Checklist for Psychotic Illness OPCRIT
system. Patients were recruited from consecutive
admissions to the psychiatric inpatient units of seven
clinical centers: (A) the Central Institute of Mental Health,
Mannheim, and the Department of Psychiatry and
Psychotherapy of the University of Bonn (n¼ 378 patients/
768 controls); (B) Department of Psychiatry, Poznan
University of Medical Sciences, Poznan, Poland (n¼ 446
patients/558 controls); (C) Alexandru Obregia Clinical
Psychiatric Hospital, Bucharest, Romania (n¼ 237 patients/
235 controls); (D) Civil Hospital Carlos Haya, Malaga, Spain
(n¼ 297 patients/401 controls); (E) Russian State Medical
University, Moscow (n¼ 331 patients/331 controls); (F)
Psychiatric Clinic, Clinical Center of the University of
Sarajevo, Sarajevo, Bosnia-Herzegovina (n¼ 124 patients/
115 controls). Ethnicity was assigned to patients and controls
on the basis of self-reported ancestry at each of the seven
recruitment sites. The given numbers reflect the sample
sizes after quality control (sample call rate 490%). This
sample was used before for replication purposes as part of a
genome-wide association study study (replication I).25
Independent replication data sets. To further strengthen
our association finding, rs1176744 was examined in
three independent genome-wide data sets.25–27 First, this
study makes use of data generated for the BOMA
(Bonn-Mannheim)-BPAD case–control cohort consisting of
682 cases and 1300 controls.25 In addition, data for two
independent, well-known BPAD studies were included. The
Wellcome Trust Case–Control Consortium BPAD study26
makes use of a cohort of 1868 patients and 2938 controls. As
rs1176744 was not available in the set of genotyped markers
for this study, the proxy rs4938058 (r2¼ 0.898) was analysed.
Finally, a sample of 987 patients and 1000 controls was
derived from the Database of Genotypes and Phenotypes
data set28 ‘Whole Genome Association Study of Bipolar Dis-
order’ (phs000017.v3.p1).27 Here, another proxy rs1176743
(r2¼ 0.919) was used.
DNA extraction and genotyping. EDTA anti-coagulated
venous blood samples were collected from all individuals.
Lymphocyte DNA was isolated by salting-out with saturated
sodium chloride solution 4, or by the use of a Chemagic
Magnetic Separation Module I (Chemagen, Baesweiler,
Germany) according to the manufacturer’s recommendations.
Genotyping was performed using the Matrix-Assisted-
Laser-Desorption/lonization–Time-Of-Flight (MALDI-TOF)-
based MassARRAY system and iPLEX Gold assays (Seque-
nom, San Diego, CA, USA). Primer sequences and assay
conditions are obtainable upon request. Single nucleotide
polymorphisms (SNPs) raw genotype data, that is, cluster
plots, were visually assessed by two investigators. SNP and
sample call rates were490%.
Statistical analyses. PLINK (v1.07; http://pngu.mgh.
harvard.edu/~purcell/plink/) was used for the analysis of
statistical association between the single SNPs and affection
status (trend test), and to test for deviations from Hardy-
Weinberg equilibrium. The SNPassoc package (http://www.
creal.cat/jrgonzalez/software.htm) for R was used to calcu-
late P-values, odds ratios (OR) and 95% confidence intervals
(CI), assuming a log-additive inheritance model adjusted for
sex.29 SPSS Statistics 17.0 (IBM Deutschland GmbH, Munich,
Germany) was used in the performance of a Cochran-
Maentel-Haentzel (CMH) meta-analysis to obtain pooled
estimates of the ORs across nationalities, and Breslow-Day
tests for homogeneity of the ORs. Significant P-values were
corrected for three tests using the Bonferroni method, but are
displayed uncorrected in text and tables. For the replication
analysis in genome-wide association study data sets, a fixed
effect model was used assuming an additive effect. To
assess putative false-negative results, a power calculation
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was carried out using Genetic Power Calculator (http://
pngu.mgh.harvard.edu/~purcell/gpc/).30
Expression analyses on the mRNA level. The total RNA
from human adult brain used in the present experiments was
either obtained commercially or was isolated from brain
tissue obtained from the German Brain Bank Brain-Net
(http://www.brain-net.net). The human fetal material was
provided by the Joint MRC Wellcome Trust Human
Developmental Biology Resource (http://www.hdbr.org).
Trizol reagent (Life Technologies, Darmstadt, Germany)
was used for the extraction of RNA, as recommended by
the manufacturer (Table 1). The experiments were approved
by the ethics committee of the University of Heidelberg.
Total RNA (100 ng) served as input material in nCounter
(Nanostring, Seattle, WA, USA) analysis using a customized
codeset, as recommended by the manufacturer. In particular,
the used codesets forHTR3A andHTR3B expression profiling
among 18 other target genes are included in Table 2
(Supplementary data). Background correction and normal-
ization of data was performed as follows. In brief, for each
sample, the average þ 2 SDS of background counts
(negative controls) was calculated. For each gene for each
sample, the average þ 2 SDS was subtracted from the
counts. Expression of HTR3A (NM_000869.5) and HTR3B
(NM_006028.3) was normalized by taking the geometric
mean of the expression of the three reference genes
ADAM9 (NM_003816.2), PGK1 (NM_000291.3) and SNX17
(NM_014748.2) into account.31
Results
In the current case–control study, 41800 cases and 2400
controls from six European countries were analyzed (Table 2).
Genotype call rates were at least 97.6% for each SNP, and
none of the tested variants deviated from Hardy-Weinberg
equilibrium in patients or controls (data not shown).
For HTR3B p.Y129S (c.386A4C, rs1176744) a pooled
odds ratio (OR) of 0.881 (95% CI¼ 0.802–0.968) was
determined in a CMH analysis, yielding a significant P-value
of 0.009 (Figure 1). This was because of an overrepresenta-
tion of the p.Y129 allele in BPAD patients. A Breslow-Day test
for homogeneity of ORs revealed no significant deviation
(P¼ 0.076). In the national subgroups, significant P-values
were detected for the Polish and Spanish cohorts in a
Cochran-Armitage trend test, under the assumption of a
log-additive inheritance model (Table 3). The P-values
Table 1 Brain tissue used for total RNA extraction followed by nCounter analysis
RNA Donor information
Number Race Gender Age COD Company
Brain Pool of 3 Caucasian Male 23 Cardiac arrest FirstChoice Human Total RNA
Survey Panel
Caucasian Male 81 Congestive heart
failure
Caucasian Female 78 Congestive heart
failure
Frontal cortex Single Caucasian Male 23 Cardiac Arrest FirstChoice Human Total RNA
Thalamus Single n.a. Female 71 Chronic obstructive
pulmonary disease
BioChain Total RNA
Right
cerebellum
Single n.a. Male 82 Aortic stenosis BioChain Total RNA
Hippocampus Single Asian Male 27 Accident BioChain Total RNA
Spinal cord Single Asian Male 27 Accident BioChain Total RNA
Striatum Single n.a. Male 20 n.a. Stratagene MVP Total RNA
Insula Pool of 15 Caucasian Male/
female
20–68 Sudden death Clontech Total RNA
Amygdala Pool of 2 Caucasian Female 21 Pneumonia BrainNet Germany
Caucasian Male 68 Cardiac arrest BrainNet Germany
Brain stem Pool of 2 Caucasian Female 21 Pneumonia BrainNet Germany
Caucasian Male 68 Cardiac arrest BrainNet Germany
Fetal brain Single n.a. n.a. F2 Induced abortion MRC Wellcome Trust
Human Developmental Biology
Resource
Fetal
cerebellum
Single n.a. n.a. F2 Induced abortion MRC Wellcome Trust
Human Developmental Biology
Resource
Fetal
thalamus
Single n.a. n.a. F2 Induced abortion MRC Wellcome Trust
Human Developmental Biology
Resource
Abbreviation: COD, cause of death.
Table 2 Number of genotyped BPAD cases and controls, totals and according
to nationality
Nationality N (cases) N (controls) N (Cases +
controls)
Bosnian-Herzegovinan 124 115 239
German 378 768 1146
Polish 446 558 1004
Romanian 237 233 471
Russian 331 333 663
Spanish 298 400 698
Total 1814 2407 4221
Abbreviation: BPAD, bipolar affective disorder.
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withstanding Bonferroni correction are highlighted in bold in
Table 3. In view of statistical power issues, the national
subgroups were not separated stratified according to sex.
However, CMH analyses showed a clear sex-specific
association. Although there was no association with the
p.Y129S variant in females, the analysis of male patients vs
controls resulted in a P-value of 0.0002 (OR¼ 0.794,
CI¼ 0.684–0.921) (Figure 1).
In a further step to strengthen our association finding,
rs1176744 (or its proxies) was examined in the three
independent genome-wide data sets BOMA-BPAD, WTCCC
(Wellcome Trust Case Control Consortium)-BPAD and
Genetic Association Information Network-BPAD, including
43500 patients and 5200 controls in total.25–27 Remarkably,
in all three samples, the p.Y129 allele was overrepresented
in patients, and a final meta-analysis revealed a P-value of
0.048 (OR¼ 0.934, fixed effects model), thereby confirming
the original association with BPAD.
No significant results were obtained for the cis-regulatory
variants HTR3A c.42C4T (rs1062613) and HTR3B c.104
102delAGA (rs3831455) in the CMH analyses (data not
shown). The former was found to be associated in the Polish
subgroup (P(log-additive) ¼ 0.002, OR¼ 0.71, 95% CI¼
0.57–0.89), and nominally associated in the Bosnian-
Herzegovinian subgroup (P(log-additive)¼ 0.025, OR¼
1.72, 95% CI¼ 1.05–2.80). However, the calculated ORs
point to different risk alleles.
To address the possibility of false-negative findings, a
power calculation was performed assuming the calculatedOR
of the HTR3B p.Y129S CMH analysis and a population risk
of 2%. This yielded a statistical power of 66% for HTR3A
c.42C4T and of 47% for HTR3B c.104_102delAGA.
Figure 1 Odds ratio (OR) distribution across nationalities for HTR3B p.Y129S (rs1176744). The number of patients and healthy controls for each country is shown along
with the respective OR and 95% confidence intervals (CI). The common P-value, OR and 95% CI (bold numbers) were determined using a Cochran-Maentel-Haenszel test.
A Breslow-Day test was performed to test for homogeneity of ORs.
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Using the nCounter technology, which measures mRNA
expression levels directly without any further enzymatic
modification of the sample,32 we detected relative expres-
sion of both subunit genes on the transcript level, that is,
HTR3A and HTR3B in total RNA samples from different
human brain regions (Figure 2). In the tested adult brain
tissues, relative code counts of the A and B subunits (code
count B/code count A ratio) was found in the following
descending order: brain stem (130), amygdala (30), frontal
cortex (15), striatum (4.7), insula (4), thalamus (2.2) and
hippocampus (1.6). The only tested tissue to show nearly
equal code counts in adult tissue was the spinal cord (0.9).
No expression was found in adult cerebellum. In the tested
fetal tissues, the B:A code count ratio was 41 in the thalamus
and 0.16 in hindbrain whereas in the cerebellum B was not
detectable at all. Interestingly, the relative expression level of
the B subunit was besides the brain stem highest in the
amygdala and frontal cortex, that is, regions in which
disturbances may lead to the manifestation of psychiatric
disorders.
Discussion
In the present study, the HTR3B p. Y129S variant was
successfully replicated overall, and showed significant asso-
ciations in the CMH analysis and in the Polish and Spanish
subgroups. The p.129Y allele was overrepresented in
patients, and this finding is consistent with previous associa-
tion data for BPAD, anorexia nervosa and major depres-
sion.12,20,21 On a functional level, homozygous 5-HT3AB
p.129Y receptors displayed a decreased 5-HT maximum
response, caused by a sevenfold decrease in single channel
mean open time, compared with homozygous 5-HT3AB
p.129S receptors.16,19 This striking difference may result in
a disease-relevant change in 5-HT3 receptor signaling.
The contribution of 5-HT3 receptors to the etiology of
psychiatric disorders is underlined by data from animal
studies. Behavioral tests in primates and rodents revealed
anxiolytic effects of 5-HT3 antagonists secondary to blockage
of the limbic hyperactivity response.33 This is consistent with
studies of 5-HT3A knockout mice, which show reduced
Table 3 Genotype counts and association statistics
SNP Study subgroup Genotypes (and frequencies) cases P-value Trend
test, d.f.¼ 1
P-value (OR, (95% CI))
Genotypes (and frequencies) controls Log additive, adjusted
according to sex
rs1062613 CC (%) CT (%) TT (%)
Bosnia-Herzegovina 70 (58) 44 (37) 6 (5)
81 (71) 30 (27) 2 (2) 0.073 0.025 (1.72, (1.06–2.80))
Germany 224 (62) 124 (34) 15 (4)
469 (62) 260 (34) 30 (4) 0.99 0.937 (0.99, (0.79–1.24))
Poland 306 (70) 114 (26) 16 (4)
335 (61) 180 (33) 33 (6) 0.01 0.002 (0.71, (0.57–0.89))
Romania 144 (63) 70 (31) 13 (6)
142 (65) 69 (31) 8 (4) 0.579 0.524 (1.11, (0.8–1.53))
Russia 205 (63) 109 (33) 11 (3)
205 (63) 105 (32) 14 (4) 0.808 0.865 (0.98, (0.74–1.28))
Spain 167 (57) 107 (36) 20 (7)
207 (52) 157 (39) 34 (9) 0.416 0.190 (0.85, (0.67–1.08))
rs3831455 ins/ins (%) ins/del (%) del/del (%)
Bosnia-Herzegovina 97 (81) 21 (18) 2 (2) 0.312 0.195 (0.69, (0.40–1.21))
82 (73) 29 (26) 2 (2)
Germany 278 (77) 80 (22) 5 (1) 0.702 0.477 (1.11, (0.84–1.47))
594 (78) 158 (21) 7 (1)
Poland 328 (75) 99 (22) 9 (2) 0.221 0.099 (1.26, (0.96–1.65))
430 (79) 107 (20) 6 (1)
Romania 174 (77) 46 (20) 6 (3) 0.591 0.812 (0.95, (0.65–1.40))
162 (75) 52 (24) 3 (1)
Russia 252 (78) 63 (19) 9 (3) 0.204 0.239 (1.22, (0.87–1.70))
261 (81) 59 (18) 4 (1)
Spain 245 (83) 47 (16) 3 (1) 0.597 0.295 (0.83, (0.58–1.18))
318 (80) 75 (19) 5 (1)
rs1176744 AA (%) AC (%) CC (%)
Bosnia-Herzegovina 54 (44) 57 (46) 13 (11) 0.3 0.152 (1.34, (0.90–1.99))
61 (54) 44 (39) 9 (8)
Germany 191 (51) 152 (41) 31 (8) 0.321 0.178 (0.87, (0.72–1.06))
355 (47) 335 (44) 73 (10)
Poland 235 (54) 157 (36) 45 (10) 0.017 0.037 (0.82, (0.68–0.99))
249 (45) 245 (44) 58 (11)
Romania 120 (51) 93 (40) 22 (9) 0.367 0.857 (0.97, (0.73–1.30))
110 (48) 105 (46) 16 (7)
Russia 154 (47) 140 (43) 34 (10) 0.889 0.950 (1.01, (0.80–1.27))
151 (45) 154 (46) 28 (8)
Spain 128 (43) 136 (46) 32 (11) 0.013 0.005 (0.73, (0.59–0.91))
142 (36) 181 (46) 73 (18)
Abbreviations: CI, confidence interval; d.f., degrees of freedom; OR, odds ratio; SNP, single nucleotide polymorphism.
Frequencies (%) were rounded off to the nearest whole number. P-values are displayed in bold if withstanding Bonferroni correction, nominally significant P-values
are shown in italics.
5-HT3 receptors in bipolar affective disorder
C Hammer et al
5
Translational Psychiatry
anxiety-like behavior.34 Further investigation of these knock-
out mice led to the conclusion that the regulation of
depression- and anxiety-related behaviors by the 5-HT3A
subunit differs between males and females.35
The effect of 5-HT3A on anxiety control has been reported to
be mediated by regulation of hypothalamic-pituitary-adrenal
responses to acute stress.36 This suggests a potential
interaction between 5-HT3A and corticotropin-releasing hor-
mone in the amygdala. Sex differences in 5-HT3A- receptor-
dependent hypothalamic-pituitary-adrenal responses in
chronically stressed mice have also been reported.36
The observed association in males in the present study is in
line with animal data.35 A feasible hypothesis is that 5-HT3
receptors are involved in the modulation of anxiety-related
behaviors, which are important phenotypes in the sympto-
matic spectrum of BPAD.
Moreover, 5-HT3 antagonist treatment in humans has
been shown to be an effective treatment for anxiety and
depression.37,38
A further aim of the present study was to gain insights into
5-HT3 receptor subunit expression in the human brain. As
outlined above, the expression of 5-HT3 receptors has mainly
been analyzed using 5-HT3-binding site-selective com-
pounds.5–8 Our data are consistent with these early human
brain ligand-binding data. Our results indicate that the
expression of both subunits appears to switch during
development. This switch in the 5-HT3A and 5-HT3B receptor
ratio is interesting, since recent studies have described the
relevance of 5-HT3 receptors to neuronal plasticity in the
cortex. Application of the 5-HT3 receptor antagonist tropise-
tron led to a specific blockade of the 5-HT3 response on Cajal-
Retzius cells in mice, and 5-HT3 receptors were shown to be
involved in postnatal dendritic maturation and neuronal
plasticity in the cortex.39 In consequence, changes in the
brain organization of variant carriers are conceivable.
Disturbed column architecture of the cortex has indeed been
reported in the brains of psychiatric patients.40 Whether or not
this is related to polymorphic changes in HTR3 genes still
awaits investigation.
Future studies are warranted to determine the functional
and structural consequences of receptor polymorphisms
in vivo. Recent studies by the present authors, using
transiently transfected human cell lines, showed that the ratio
between the subunits A and B determines receptor composi-
tion and consequently the formation of homomeric and
heteromeric B subunits.19,41
We were able to confirm co-expression of both 5-HT3
subunits in brain regions involved in memory, cognition and
anxiety control, that is, the frontal cortex, the hippocampus
and the amygdala, respectively. Murine studies have shown
that 70–80% of 5-HT3 receptors are located presynaptically
and are associated with axons and nerve terminals, with the
exception of those in the hippocampus, which are mainly
postsynaptic and located in somatodendritic regions.42 The
high presynaptic expression of 5-HT3 receptors is consistent
with their physiological role in neurotransmitter release
(dopamine, cholecystokinin, glutamate, acetylcholine and
gamma-aminobutyric acid (GABA)).43 Accordingly, both the
excitatory and the inhibitory effects of 5-HT3R activation are
mediated by activation of excitatory or inhibitory interneur-
ons.44 For example, 5-HT3R activation of GABAergic
interneurons innervating the amygdala is thought to exert
an inhibitory influence on amygdala activity, whereas the
activation of excitatory glutamatergic interneurons is hy-
pothesized to have the opposite effect.44 However, the
situation in humans remains unknown. To date, systematic
analysis has been hampered by the lack of specific
antibodies.
Taken together, our results support the hypothesis that the
HTR3B p.Y129S variant is implicated in BPAD, and the
association could be replicated in a meta-analysis utilizing
large published genome-wide association study data sets.
Future studies are warranted to investigate a possible effect of
this common genetic variant on further relevant neuropsy-
chiatric phenotypes such as anxiety, stress response and
depressive episodes, as well as memory and cognition. In
doing so, possible gender-specific effects should also be
taken into account.
In contrast to the HTR3B variant p.Y129S, the variants
HTR3A c.42C4T (rs1062613) and HTR3B c.104
102delAGA (rs3831455) were not replicated in our study
overall. In fact, for the HTR3A variant, association analysis in
the national subgroups generated contradictory results.
Whereas pilot studies into BPAD, irritable bowel syndrome
and eating disorders have implicated the less frequent T allele
in the development of the disease phenotypes,14,20,45 in the
present study the C allele occurred more often in Polish
patients. Although the nominally significant association in the
subgroup from Bosnia-Herzegovina replicated earlier
results (P(log-additive) ¼ 0.025), the sample was small and
probably lacked statistical power to detect true positives.
Hence, our study does not support the hypothesis that
HTR3A c.42C4T SNP or the small deletion HTR3B
c.104_102delAGA are involved in the etiology of BPAD.
Nevertheless, the retrospective power calculation for the
whole sample indicates that our study cohort may have been
too small to detect minor effects.
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Figure 2 HTR3A and HTR3B mRNA expression profiling. mRNA levels
were directly quantified using the nCounter technology. (a) Comparison of adult
and fetal brain overall; (b) fetal brain areas and (c) adult brain regions. Abbreviations:
CB, cerebellum; HB, hind brain; HIP, hippocampus; THA, thalamus; INS, insula; STRI,
striatum; SC, spinal cord; AMY, amygdala; BS, brain stem; FC, frontal cortex.
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In conclusion, the present study replicated the functional
HTR3B variant p.Y129S as a predisposing factor for BPAD.
Future studies should investigate the precise role ofHTR3B in
this disorder. The sex specificity of the association points to a
putative function in the hypothalamic-pituitary-adrenal axis,
resulting in anxiety-related phenotypes. Interestingly, differing
code-count ratios of the A and B subunits were found in
various adult and fetal brain regions, suggesting differences in
receptor function and composition in the developing, com-
pared with the adult brain.
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